AVXL

Anavex Life Sciences Corp

1.24

Oct 30 • 12:38 PM ET -0.06 (-4.76%)

Healthcare Biotechnology USA Micro NASD

Peers: CGTX ABOS ANVS ACIU PRTA ACOG INMB ACAD TSHA BIIB

| Held by: VTI IWM VXF VTWO IWN IBB SCHA VHT IWC IWO

Index	RUT
Market Cap	114.77M
Enterprise Value	-3.56M
Income	-13.02M
Sales	0.00M
Book/sh	1.21
Cash/sh	1.28
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	34
IPO	Aug 02, 2006

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.02
P/C	0.97
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	15.62
Current Ratio	15.62
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.15
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	4.47% -3.79%
Sales past 3/5Y	- -
EPS Y/Y TTM	73.28%
Sales Y/Y TTM	-
EPS Q/Q	154.29%
Sales Q/Q	-
Earnings	Aug 25 BMO
EPS/Sales Surpr.	- -

Insider Own	1.71%
Insider Trans	0.00%
Inst Own	39.87%
Inst Trans	-3.52%
ROA	-11.70%
ROE	-12.80%
ROIC	-11.58%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-12.08%
SMA50	-42.25%
SMA200	-59.96%
Trades

Shs Outstand	92.70M
Shs Float	91.12M
Short Float	13.77%
Short Ratio	12.03
Short Interest	12.55M
52W High	8.35 -85.17%
52W Low	1.14 8.61%
Volatility	4.58% 7.40%
ATR (14)	0.11
RSI (14)	22.15
Beta	1.18
Rel Volume	0.93
Avg Volume	1.04M
Volume	494,675

Perf Week	-6.91%
Perf Month	-34.49%
Perf Quarter	-58.03%
Perf Half Y	-62.71%
Perf YTD	-65.22%
Perf Year	-84.58%
Perf 3Y	-77.49%
Perf 5Y	-93.39%
Perf 10Y	-58.17%
Recom	1.00
Target Price	20.00
Prev Close	1.30
Price	1.24
Change %	-4.76%

Consensus

Strong Buy

Avg. Price Target

$20.00

Implied Upside

+1,515.4%

Analysts11incl. previous ratings

Rating Distribution10 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 04, 2026	Initiated	RRodman & Renshaw	Buy	$20	+1,515.4%
Dec 06, 2022	Downgrade	CCantor Fitzgerald	Overweight → Neutral	$16 → $11	+788.5%
Jun 23, 2022	Initiated	BBerenberg	Buy	$40	+3,130.8%
Sep 23, 2021	Initiated	BBTIG Research	Buy	$35	+2,726.9%
Dec 16, 2020	Reiterated	HH.C. Wainwright	Buy	$14 → $17	+1,273.1%
Sep 28, 2020	Initiated	LLadenburg Thalmann	Buy	$12	+869.2%
Feb 27, 2020	Initiated	CCantor Fitzgerald	Overweight
Jun 18, 2019	Initiated	JJanney	Buy
May 16, 2018	Resumed	MMaxim Group	Buy	$5 → $7	+465.4%
Mar 08, 2018	Initiated	RROTH Capital	Buy	$6	+384.6%
Feb 13, 2018	Reiterated	MMaxim Group	Buy	$14 → $5	+303.8%
Sep 29, 2017	Resumed	NNoble Financial	Buy	$15	+1,111.5%
Feb 07, 2017	Initiated	NNoble Financial	Buy	$16	+1,192.3%
Mar 29, 2016	Initiated	FFBR Capital	Outperform	$10	+707.7%

Oct-27-26 10:34PM	AVXL Stockholders Have Rights - If You Lost Money Investing in Anavex Life Sciences Corp. Contact Robbins LLP for Information About Recovering Your Losses (PR Newswire)
Oct-21-26 07:41AM	Aevex stock drops 5% as US Navy halts $130M drone boat program (Investing.com)
Oct-20-26 04:00PM	Anavex Provides Corporate Update, Announces Completion of Clinical Conduct of ADME and DDI Clinical Studies (GlobeNewswire) +8.80%
Oct-16-26 01:52PM	Did You Lose Money Investing in Anavex Life Sciences Corp.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AVXL (Newsfile) -11.49%
09:33AM	Anavex Receives FDA IND Clearance for Blarcamesine in Fragile X Syndrome, Enabling Phase 2a Trial (InvestorsHub)
04:00PM	Loading…
Oct-15-26 04:00PM	Anavex Receives FDA Clearance of its IND Application for Blarcamesine in Fragile X Syndrome (GlobeNewswire)
Oct-14-26 06:00PM	AVXL Investors: Anavex Life Sciences Corp. Shares Declined By $0.19 On August 31, 2026 - Contact Kirby McInerney LLP to Discuss Your Rights (Business Wire)
Oct-12-26 02:17AM	Anavex Life Sciences Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AVXL (PR Newswire)
Oct-08-26 03:00AM	Kaplan Fox Encourages Anavex Life Sciences Corp. (AVXL) Investors with Significant Losses to Contact the Firm Before November 30, 2026 (Newsfile)
Oct-05-26 01:38AM	Anavex Life Sciences Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AVXL (PR Newswire) -9.62%
Sep-30-26 03:00PM	Anavex Life Sciences Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights AVXL (Business Wire) -14.41%
Sep-24-26 10:00AM	Anavex Stockholders Elect All of the Company's Director Nominees at 2026 Annual Meeting (GlobeNewswire)
Sep-14-26 08:30AM	Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Six of Anavex's Highly Qualified Director Nominees (GlobeNewswire)
Sep-08-26 08:00AM	Anavex Life Sciences to Host Investor Call on Wednesday, September 9, 2026, at 4:00 PM ET (GlobeNewswire)
Sep-02-26 04:00PM	Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement (GlobeNewswire)
10:46AM	Loading…
Aug-25-26 10:46AM	Anavex Life Sciences Advances Alzheimer's Phase 3 Planning as Cash Runway Extends Into Fiscal 2028 (InvestorsHub) +14.47%
08:11AM	Anavex Life Sciences: Fiscal Q3 Earnings Snapshot (Associated Press)
08:00AM	Anavex Life Sciences Reports Third Fiscal Quarter 2026 Financial Results and Business Update (GlobeNewswire)
Aug-19-26 12:32PM	Real Parkinsons Disease Hope from Jupiter Neurosciences (Exec Edge) +5.94%
Aug-17-26 11:04AM	Anavex Urges Shareholders to Back Six Director Nominees Ahead of 2026 Annual Meeting (InvestorsHub)
08:00AM	Anavex Life Sciences Mails Letter to Stockholders Reinforcing Relevant Experience of All Six Director Nominees (GlobeNewswire)
Aug-11-26 11:13AM	Anavex Life Sciences Faces September Board Vote as Blarcamesine Regulatory Strategy Advances (InvestorsHub)
08:00AM	Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders (GlobeNewswire)
Aug-03-26 10:09AM	Anavex Announces Board Refresh as It Seeks to Strengthen Governance and Advance Drug Pipeline (InvestorsHub) +7.27%
08:00AM	Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation (GlobeNewswire)
Jul-30-26 11:05AM	Anavex Life Sciences Reports Preliminary Q2 2026 Results and Advances FDA Strategy for Blarcamesine (InvestorsHub) +8.43%
08:14AM	Anavex Life Sciences: Fiscal Q2 Earnings Snapshot (Associated Press)
08:00AM	Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
May-22-26 08:00AM	Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification (GlobeNewswire)
May-06-26 10:52AM	CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus (InvestorsHub)
07:00AM	Loading…
07:00AM	Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer (GlobeNewswire)
May-04-26 09:43AM	AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls (The Fly)
Apr-14-26 07:30AM	Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease (GlobeNewswire)
Apr-07-26 07:30AM	Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-26 07:30AM	Anavex Life Sciences Provides Comprehensive Regulatory Update (GlobeNewswire)
Mar-25-26 07:30AM	Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease (GlobeNewswire) -34.61%
Mar-23-26 07:30AM	Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease (GlobeNewswire) +9.36%
Mar-20-26 07:30AM	New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer's Disease (GlobeNewswire)
Mar-17-26 07:30AM	Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference (GlobeNewswire)
Mar-05-26 08:27AM	Anavex Life Sciences Touts Oral Alzheimers Drug Blarcamesine Data, Cash Runway at Healthcare Conference (MarketBeat)
Mar-04-26 01:32PM	What's Going On With Anavex Life Sciences Stock On Wednesday? (Benzinga) +6.61%
Mar-03-26 07:30AM	Anavex Life Sciences to Present at the Citizens Life Sciences Conference (GlobeNewswire)
Mar-02-26 09:40AM	Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-25-26 07:30AM	Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference (GlobeNewswire)
Feb-23-26 07:30AM	Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors (GlobeNewswire)
Feb-12-26 12:00PM	Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know (Zacks)
09:40AM	Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-09-26 10:06AM	Anavex Life Sciences Q1 Earnings Call Highlights (MarketBeat) +6.10%
07:35AM	Anavex Life Sciences: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update (GlobeNewswire)
Feb-03-26 07:30AM	Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 (GlobeNewswire)
Jan-15-26 04:06AM	Anavex Life Sciences Highlights Oral Alzheimers Drug Blarcamesine, Precision Strategy at JPM Conference (MarketBeat)
Jan-13-26 07:30AM	Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease (GlobeNewswire) +8.16%
Jan-08-26 07:30AM	Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology (GlobeNewswire)
Jan-06-26 07:30AM	Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program (GlobeNewswire)
Dec-18-25 07:30AM	Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion (GlobeNewswire)
Dec-12-25 04:05PM	Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease (GlobeNewswire)
Dec-02-25 09:35AM	Down 50.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Anavex Life Sciences (AVXL) (Zacks)
Nov-26-25 07:30AM	Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) +11.56%
Nov-25-25 04:00PM	Anavex Life Sciences Corp (AVXL) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com) +12.34%
07:47AM	Anavex Life Sciences: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update (GlobeNewswire)
Nov-19-25 07:30AM	Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference (GlobeNewswire)
Nov-18-25 07:30AM	Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025 (GlobeNewswire)
Nov-14-25 07:30AM	Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease (GlobeNewswire) -35.94%
Oct-29-25 07:30AM	Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group (GlobeNewswire)
Oct-10-25 07:30AM	Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference 'Connecting Science and Communities: The Future of Dementia Care' (GlobeNewswire)
Oct-02-25 07:35AM	Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX3-71 Program (GlobeNewswire)
07:30AM	Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX3-71 for the Treatment of Schizophrenia (GlobeNewswire)
Sep-30-25 08:30AM	Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial (GlobeNewswire)
Sep-24-25 08:38PM	H.C. Wainwright Reiterates Its 'Buy' Rating on Anavex Life Sciences Corp. (AVXL) with a $42 Price Target (Insider Monkey)
Sep-09-25 07:30AM	Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial (GlobeNewswire) +9.73%
Sep-02-25 07:30AM	Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025 (GlobeNewswire)
Aug-26-25 07:30AM	Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine (GlobeNewswire)
Aug-20-25 07:31AM	Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows (Benzinga)
07:30AM	Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease (GlobeNewswire)
Aug-13-25 01:00PM	Anavex Life Sciences Corp (AVXL) Q3 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-12-25 01:59PM	Anavex Life Sciences: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -5.02%
07:30AM	Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-25 07:30AM	Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 (GlobeNewswire)
Aug-01-25 08:29AM	Anavexs blarcasemine nets win in Phase IIb/III Alzheimers extension study (Clinical Trials Arena)
Jul-31-25 07:31AM	Anavex Life Sciences: Early Blarcamesine Treatment Cuts Alzheimer's Progression by 20 Months (Benzinga)
07:30AM	Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease (GlobeNewswire)
Jul-10-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Anavex Life Sciences (AVXL) is a Great Choice (Zacks)
Jul-04-25 09:40AM	Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year? (Zacks)
May-14-25 05:01PM	Anavex Life Sciences Corp (AVXL) Q2 2025 Earnings Call Highlights: Promising Alzheimer's Data ... (GuruFocus.com)
07:30AM	Anavex Life Sciences to Participate at Upcoming Healthcare Conferences (GlobeNewswire)
May-13-25 07:37AM	Anavex Life Sciences: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -5.03%
07:30AM	Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 08:25AM	Is Anavex Life Sciences Corp. (AVXL) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-06-25 07:30AM	Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 (GlobeNewswire) -7.63%
May-01-25 07:30AM	Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX3-71 for the Treatment of Schizophrenia (GlobeNewswire)
Apr-30-25 07:30AM	Anavex Life Sciences to Participate in The Citizens Life Sciences Conference (GlobeNewswire)
Apr-23-25 07:30AM	Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board (GlobeNewswire)
Apr-21-25 04:41PM	Anavex Life Sciences Corp (AVXL) Q1 2025 Earnings Call Highlights: Promising Alzheimer's Data ... (GuruFocus.com) +5.14%
07:30AM	Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East (GlobeNewswire)
Apr-13-25 05:13AM	Anavex: A Small Bit Of Progress Against Alzheimer's Disease (Seeking Alpha)
Apr-11-25 03:00PM	Undercovered Dozen: VICI Properties, General Dynamics, LandBridge, Anavex + (Seeking Alpha)
Apr-07-25 06:31PM	Anavex: Understanding Their Alzheimer's Open-Label Extension Data Skeptically (Seeking Alpha) -8.76%
12:49PM	AD/PD 2025: Long-term data shows Anavexs Blarcamesine benefits in early Alzheimers (Clinical Trials Arena)

Show Previous News

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

CGAMs. Sandra Boenisch CPA

Interim Chief Executive OfficerDr. Terrie Kellmeyer Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVXL

Anavex Life Sciences Corp

Upgrade your Finviz experience